882 results on '"Costa, Daniel B."'
Search Results
102. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling
103. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
104. Special Issue on Unmanned Aerial Vehicle (UAV)-Enabled Green Communications and Networking
105. Safeguarding MIMO Communications with Reconfigurable Metasurfaces and Artificial Noise
106. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population
107. Molecular Testing in Lung Cancer: The Time Is Now
108. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
109. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
110. Accurate approximations to the sum of generalized random variables and applications in the performance analysis of diversity systems
111. IRS-Assisted Massive MIMO-NOMA Networks with Polarization Diversity
112. Safeguarding MIMO Communications with Reconfigurable Metasurfaces and Artificial Noise
113. Optimal Carrier Sensing Range in Coexisting Wireless Networks
114. Understanding UAV-Based WPCN-Aided Capabilities for Offshore Monitoring Applications
115. Approximate Distributions of the Residual Self-Interference Power in Multi-Tap Full-Duplex Systems
116. An improved closed-form approximation to the sum of arbitrary Nakagami-m variates
117. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
118. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia
119. The Design of Efficient, Low-Complexity Cooperative Diversity Schemes from Different Perspectives
120. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
121. Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590
122. Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
123. Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
124. Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
125. Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19
126. Physical-Layer Security of SIMO Communication Systems over Multipath Fading Conditions
127. User Fairness in Wireless Powered Communication Networks With Non-Orthogonal Multiple Access
128. Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer
129. Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
130. Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non–Small-Cell Lung Cancer
131. Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
132. Peripheral Effects of Iron Deficiency
133. EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer
134. Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
135. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
136. Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation
137. ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
138. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
139. Performance analysis of dual-hop AF relaying over [formula omitted]-[formula omitted] fading channels
140. ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers
141. KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma
142. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1–Positive Lung Cancer
143. The α-η-κ-F Composite Fading Distribution
144. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
145. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
146. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
147. What Role Do Intelligent Reflecting Surfaces Play in Multi-Antenna Non-Orthogonal Multiple Access?
148. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations
149. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
150. The rapidly evolving landscape of biomarker testing in non–small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.